Avid tapped to produce Enzyvant's rare disease candidate

It's Avid's latest move aimed at building a presence in the CDMO space.

By Jacob Bell • Feb. 22, 2018

Gilead taps Sangamo to expand cell therapy after Kite buy

The big biotech is trying to expand its know-how and pipeline in its recently acquired area of cell therapies.

By Lisa LaMotta • Feb. 22, 2018

Biohaven teams up with Catalent on CGRP oral drug delivery

The drugmaker will use Catalent's fast-dissolving technology for rapid delivery of its migraine medication.

By Suzanne Elvidge • Feb. 22, 2018

Merck buys virus maker to flesh out I/O pipeline

Viralytics hands Merck a mid-stage oncolytic virus drug that's already being tested in combination with Keytruda.

By Jacob Bell • Feb. 21, 2018

Takeda surfs a potential $2B Wave of acquisitions

Japan's Takeda gets a boost to its neurology pipeline with the deal to commercialize nucleic acid therapies.

By Suzanne Elvidge • Feb. 21, 2018

AstraZeneca taps Ionis for second antisense drug

The British pharma has gone back to the biotech for an antisense therapy directed at kidney disease.

By Lisa LaMotta • Feb. 20, 2018

Prescribed Reading: Landscape-changing deals and Alzheimer's shake-ups

A relatively large research collaboration could change the deal landscape. Elsewhere, the Alzheimer's development picture is getting a makeover. 

By Lisa LaMotta • Feb. 16, 2018

Roche buys cancer data company Flatiron Health for $1.9B

Acquiring the tech unicorn will help Roche better use real-world evidence in the development of cancer drugs, while building its data analytics expertise. 

By Suzanne Elvidge • Feb. 16, 2018

Charles River boosts CRO chops with $800M deal for MPI

Acquiring MPI Research should raise Charles Rivers' profits as early as this year and expand its business with biotech.

By Ned Pagliarulo • Feb. 15, 2018

Bioverativ taps new manufacturer as it steps out of Biogen's shadow

The spinoff-turned-Sanofi-company could pay more than $100 million to Oxford BioMedica for lentiviral vector production.

By Jacob Bell • Feb. 15, 2018

Bristol-Myers bets $1.85B on combo potential of Nektar cancer drug

It's a substantial upfront sum to gain access to Nektar's early-stage candidate, reflecting the growing importance of building an edge in combination immunotherapy.

By Ned Pagliarulo • Feb. 14, 2018

Avid sells off cancer assets, transitioning to CDMO

Boston biotech Oncologie will buy Avid's pipeline oncologics, completing the latter company's transition from drugmaker to contract manufacturer. 

By Suzanne Elvidge • Feb. 13, 2018

Roivant and Poxel sign $650M diabetes deal

While Roivant has programs in endocrinology, the licensing pact for imeglimin pulls the Swiss biotech into the diabetes arena.

By Suzanne Elvidge • Feb. 13, 2018

Fewer regs could lower drug costs: White House council

The Council of Economic Advisers also suggested creating an independent agency to oversee the 340B prescription drug program.  

By Les Masterson • Feb. 12, 2018

Allergan picks up Australian biotech Elastagen in $95M deal

Buying Elastagen's tissue repair platform fits with Allergan's "bolt-on" approach to dealmaking and further expands the pharma's medical aesthetics capabilities. 

By Suzanne Elvidge • Feb. 12, 2018

SeaGen, Pieris ink deal for bispecific I/O drugs

For $30 million upfront and $1.2 billion in potential milestones, SeaGen gains the rights to advance three candidates created through the collaboration.

By Jacob Bell • Feb. 9, 2018

Prescribed Reading: Earnings point to restructuring, not M&A

As pharma companies continued to report full-year earnings, the M&A spree has stopped and the focus has shifted to fixing up the pipeline. 

By Lisa LaMotta • Feb. 9, 2018

J&J strikes potential $1B JAK inhibitor deal with Theravance

The biotech will get $100 million upfront and up to $900 million in milestones should J&J opt into the program. 

By Lisa LaMotta • Feb. 7, 2018

Prescribed Reading: Tax changes disappoint, ho-hum earnings

Recent earnings reports shine a light on investor expectations for the tax code changes and M&A in 2018.

By Lisa LaMotta • Feb. 2, 2018

Boehringer strikes Jardiance outcomes deal with Prime PBM

Intense competition in the diabetes drugs market has pushed manufacturers to search for ways to gain an edge, including value-based deals with payers.

By Jacob Bell • Jan. 31, 2018

SeaGen picks up Cascadian in $614M deal

The Seattle biotech is picking up its neighbor to gain a third late-stage asset. 

By Lisa LaMotta • Jan. 31, 2018

Boosted by tax reform, Lilly looking for ways to spend $9B

While the Indianapolis drugmaker didn't drop any hints, executives said the company isn't planning to hold on to the newly unlocked cash for long.

By Ned Pagliarulo • Jan. 31, 2018

How Amazon, JPM and Berkshire could disrupt healthcare (or not)

"News of three corporate giants forming an independent healthcare company proves every business is a healthcare business," said David Vivero, CEO of digital health startup Amino.

By Shannon Muchmore, Daphne Howland & Jeff Byers • Jan. 31, 2018

BridgeBio picks up shelved Novartis drug, kicks off new subsidiary

New BridgeBio subsidiary QED Therapeutics will develop Novartis' infigratinib in cancer and skeletal dysplasias.

By Suzanne Elvidge • Jan. 31, 2018

Pfizer benefits from tax reform, still vague on M&A

The big pharma expects to bring back as much as $24 billion in cash from overseas, but is still mum on how it will be spent.

By Lisa LaMotta • Jan. 30, 2018